EE200000151A - Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon - Google Patents

Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Info

Publication number
EE200000151A
EE200000151A EEP200000151A EEP200000151A EE200000151A EE 200000151 A EE200000151 A EE 200000151A EE P200000151 A EEP200000151 A EE P200000151A EE P200000151 A EEP200000151 A EE P200000151A EE 200000151 A EE200000151 A EE 200000151A
Authority
EE
Estonia
Prior art keywords
amino
pharmaceutical composition
host cell
production method
expression vector
Prior art date
Application number
EEP200000151A
Other languages
English (en)
Inventor
Proost Paul
Struyf Sofie
Van Damme Jo
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000151A publication Critical patent/EE200000151A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EEP200000151A 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon EE200000151A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (en) 1997-09-29 1997-09-29 Amino-terminal truncated c-c chemokines as chemokine antagonist
EP97122471A EP0905240A1 (en) 1997-09-29 1997-12-19 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP98104216A EP0905241A1 (en) 1997-09-29 1998-03-10 Amino-terminally truncated c-c chemokines as chemokine antagonists
PCT/EP1998/006143 WO1999016877A1 (en) 1997-09-29 1998-09-28 Amino-terminally truncated rantes as chemokine antagonists

Publications (1)

Publication Number Publication Date
EE200000151A true EE200000151A (et) 2001-02-15

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200000152A EE200000152A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
EEP200000151A EE200000151A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EEP200000152A EE200000152A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Country Status (29)

Country Link
US (5) US6905676B2 (et)
EP (6) EP0906954A1 (et)
JP (2) JP4230659B2 (et)
KR (2) KR100542934B1 (et)
CN (3) CN1233415C (et)
AR (2) AR013528A1 (et)
AT (3) ATE264390T1 (et)
AU (2) AU750341B2 (et)
BG (2) BG64679B1 (et)
BR (2) BR9812394A (et)
CA (2) CA2304827A1 (et)
CY (1) CY1110927T1 (et)
CZ (2) CZ299478B6 (et)
DE (3) DE69823218T2 (et)
DK (3) DK1021541T3 (et)
EA (2) EA003940B1 (et)
EE (2) EE200000152A (et)
ES (3) ES2287601T3 (et)
HK (3) HK1032426A1 (et)
HU (2) HU226414B1 (et)
IL (2) IL135351A (et)
NO (2) NO20001584D0 (et)
NZ (3) NZ503235A (et)
PL (2) PL196427B1 (et)
PT (3) PT1021541E (et)
SK (2) SK286495B6 (et)
UA (2) UA73080C2 (et)
WO (2) WO1999016877A1 (et)
ZA (2) ZA988676B (et)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU1616499A (en) 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU1259501A (en) * 1999-10-25 2001-05-08 Euroscreen S.A. Processed human chemokines phc-1 and phc-2
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
US7553483B2 (en) 2001-12-17 2009-06-30 Merck Serono Sa Chemokine mutants acting as chemokine antagonists
EP1631680A2 (en) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
US20130053257A1 (en) * 2010-02-08 2013-02-28 Paul E. Oran RANTES Multiplexed Assay, RANTES Variants Related to Disease, and RANTES Variants Related to Enzymatice Activity
JP5975886B2 (ja) 2010-03-11 2016-08-23 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
CN112469430A (zh) 2018-05-28 2021-03-09 日内瓦大学 抑制大脑炎症的方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311107A3 (en) 1987-10-08 1990-04-18 Stichting REGA V.Z.W. Anti-hiv active 3'-fluoro-purine-2',3'-dideoxyribosides
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
PL182786B1 (pl) * 1994-12-08 2002-02-28 Glaxo Group Ltd Polipeptyd, sekwencja kwasu nukleinowego, wektor, komórka gospodarza, środek farmaceutyczny, oraz sposób otrzymywania polipeptydu
WO1997025427A1 (en) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mcp-2)
JP2000508527A (ja) * 1996-03-27 2000-07-11 アイコス コーポレイション 単球走化性タンパク質―５物質及び方法
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
CA2305017A1 (en) 1999-04-08
KR100560275B1 (ko) 2006-03-10
KR100542934B1 (ko) 2006-01-11
US6905676B2 (en) 2005-06-14
PT1439231E (pt) 2007-08-20
JP2001518297A (ja) 2001-10-16
UA73080C2 (en) 2005-06-15
CZ20001147A3 (cs) 2000-09-13
CN1490049A (zh) 2004-04-21
PT1021541E (pt) 2004-07-30
JP4233214B2 (ja) 2009-03-04
NO20001584L (no) 2000-03-27
PL196427B1 (pl) 2008-01-31
BG104267A (en) 2000-11-30
HK1032426A1 (en) 2001-07-20
CN1233415C (zh) 2005-12-28
EP0905240A1 (en) 1999-03-31
US20030124677A1 (en) 2003-07-03
EA003940B1 (ru) 2003-10-30
ZA988675B (en) 1999-11-24
ES2287601T3 (es) 2007-12-16
ZA988676B (en) 1999-12-03
HU226468B1 (en) 2008-12-29
CN1271386A (zh) 2000-10-25
CN1148447C (zh) 2004-05-05
HK1032425A1 (en) 2001-07-20
EP1019507B1 (en) 2004-03-31
PL339545A1 (en) 2000-12-18
CY1110927T1 (el) 2015-06-10
PL197569B1 (pl) 2008-04-30
ATE368742T1 (de) 2007-08-15
AU750606B2 (en) 2002-07-25
BR9812565A (pt) 2000-08-01
CN1145693C (zh) 2004-04-14
CA2304827A1 (en) 1999-04-08
DK1021541T3 (da) 2004-08-02
US20050201977A1 (en) 2005-09-15
DE69822856D1 (de) 2004-05-06
HUP0003505A3 (en) 2005-11-28
JP2001518296A (ja) 2001-10-16
DE69838188T2 (de) 2007-11-22
EA200000378A1 (ru) 2000-10-30
HUP0003505A2 (hu) 2001-02-28
HUP0003563A3 (en) 2005-11-28
ES2215324T3 (es) 2004-10-01
HU226414B1 (en) 2008-11-28
IL135352A (en) 2006-08-20
NZ516027A (en) 2003-05-30
WO1999016877A1 (en) 1999-04-08
NO20001584D0 (no) 2000-03-27
US20030119148A1 (en) 2003-06-26
SK4512000A3 (en) 2000-09-12
US7338653B2 (en) 2008-03-04
EA200000379A1 (ru) 2000-10-30
KR20010024213A (ko) 2001-03-26
IL135351A (en) 2006-08-20
SK286439B6 (sk) 2008-10-07
NO20001609L (no) 2000-03-28
US7326411B2 (en) 2008-02-05
EP1439231A2 (en) 2004-07-21
ATE264390T1 (de) 2004-04-15
NO20001609D0 (no) 2000-03-28
WO1999016876A1 (en) 1999-04-08
EP1439231A3 (en) 2004-12-22
PL339559A1 (en) 2000-12-18
SK286495B6 (sk) 2008-11-06
DE69823218D1 (de) 2004-05-19
EP0905241A1 (en) 1999-03-31
CN1271385A (zh) 2000-10-25
HK1062637A1 (en) 2004-11-19
ES2218860T3 (es) 2004-11-16
US20050164936A1 (en) 2005-07-28
CZ299479B6 (cs) 2008-08-06
AU9442098A (en) 1999-04-23
DE69838188D1 (de) 2007-09-13
AR013529A1 (es) 2000-12-27
CZ20001146A3 (cs) 2000-09-13
DE69822856T2 (de) 2004-08-19
EP1021541A1 (en) 2000-07-26
CZ299478B6 (cs) 2008-08-06
DK1439231T3 (da) 2007-11-05
EP1021541B1 (en) 2004-04-14
NZ503234A (en) 2002-06-28
US20050220790A1 (en) 2005-10-06
EA003942B1 (ru) 2003-10-30
HUP0003563A2 (hu) 2001-02-28
DE69823218T2 (de) 2004-08-26
US6977071B2 (en) 2005-12-20
BG104266A (en) 2000-11-30
BG64757B1 (bg) 2006-02-28
DK1019507T3 (da) 2004-07-19
PT1019507E (pt) 2004-06-30
BG64679B1 (bg) 2005-11-30
AU9747498A (en) 1999-04-23
UA73081C2 (en) 2005-06-15
JP4230659B2 (ja) 2009-02-25
AU750341B2 (en) 2002-07-18
SK4502000A3 (en) 2000-09-12
AR013528A1 (es) 2000-12-27
KR20010024214A (ko) 2001-03-26
EP1019507A1 (en) 2000-07-19
ATE263242T1 (de) 2004-04-15
BR9812394A (pt) 2000-09-12
EE200000152A (et) 2001-02-15
NZ503235A (en) 2002-08-28
EP1439231B1 (en) 2007-08-01
EP0906954A1 (en) 1999-04-07

Similar Documents

Publication Publication Date Title
EE200000151A (et) Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
BR9813692B1 (pt) processo para produzir uma vacina da proteìna e2 de pestivìrus recombinante em cultura de células de inseto, e, vacina da subunidade e2.
AU4567499A (en) Novel mtbx protein and nucleic acid molecules and uses therefor
EP1007706A4 (en) RNA-BINDING PROTEIN AND BINDING POINT USEFUL FOR THE EXPRESSION OF RECOMBINANT MOLECULES
EP0760849A4 (en) RECOMBINANT BACTERICIDAL PERMEABILITY (BPI) AND LIPOSACCHARIDE (LBD) RECOMBINANT PROTEINS, MOLECULES ENCODING THE SAME, THEIR PRODUCTION METHODS AND THEIR USES
EE200000355A (et) IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine
EP0749312A4 (en) DIROFILARIA IMMITIS - Gp29 - PROTEINS, NUCLEIC ACID MOLECULES AND THEIR USE
EP1001964A4 (en) TANGO-78, TANGO-79 AND TANGO-81 NUCLEIC ACID MOLECULES
FI953640A (fi) Termostabiilit ksylanaasi-DNA, proteiini ja käyttömenetelmät
AU7147898A (en) (dirofilaria) and (brugia) ankyrin proteins, nucleic acid molecules, and uses thereof
IL138216A0 (en) Novel fdrg protein and nucleic acid molecules and uses therefor
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
DK0676413T3 (da) Inteferon-alfa/beta-bindingsprotein, dets fremstilling og anvendelse
AU1818399A (en) Novel flea epoxide hydrolase nucleic acid molecules, proteins and uses thereof
EP0846165A4 (en) NOVEL PROTEINS AND NUCLEIC ACID MOLECULES OF FILARIID NEMATODE CYSTEIN PROTEASE AND THEIR USE
AU2801597A (en) Flea protease proteins, nucleic acid molecules, and uses thereof
ZA979390B (en) Polypeptides comprising domains of the GAX protein which are involved in the repression of transcription and/or which interact with other proteins, corresponding nucleic acids and their uses.
DE69738977D1 (de) Neues fusionsprotein, dafuer kodierendes gen, rekoerwendung
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
AU4826899A (en) Novel msp-5 protein and nucleic acid molecules and uses therefor
AU5312699A (en) Novel mp-7 protein and nucleic acid molecules and uses therefor
EP1385991A4 (en) HUMAN INSULATED ENZYMATIC PROTEINS, NUCLEIC ACID MOLECULES ENCODING THE SAME AND USES THEREOF
AU2001257287A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
EP1383876A4 (en) ISOLATED HUMAN ENZYME PROTEINS, HUMAN ENZYME PROTEIN CODING NUCLEIC ACID MOLECULES, AND USES THEREOF

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner